B-cell lymphoma, unclassifiable, with features intermediate between diffuse large b-cell lymphoma and classical Hodgkin lymphoma
MONDO:0003658A group of lymphomas displaying molecular, morphologic, immunophenotypic, and clinical overlap between classical Hodgkin lymphoma and diffuse large B-cell lymphoma. This term particularly applies to mediastinal lymphomas with overlapping features of mediastinal (thymic) large B-cell lymphoma and classical Hodgkin lymphoma.
Also known as: B-cell lymphoma, unclassifiable, with features Intermediate between diffuse large B-cell lymphoma and Classic Hodgkin lymphoma, B-cell lymphoma, unclassifiable, with features Intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma, Gray zone lymphoma, Grey zone lymphoma, Hodgkin-like anaplastic large cell lymphoma, large B-cell lymphoma with Hodgkin features
1903 clinical trials for this condition and its sub-types, 11 tagged with B-cell lymphoma, unclassifiable, with features intermediate between diffuse large b-cell lymphoma and classical Hodgkin lymphoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large b-cell lymphoma and classical Hodgkin lymphoma
-
Mediastinal gray zone lymphoma 1 trial
-
New drug cocktail shows promise for Tough-to-Treat lymphoma
Disease control CompletedThis early-stage trial tested a combination of two drugs, lenalidomide and blinatumomab, in 35 adults with non-Hodgkin lymphoma that had come back or stopped responding to treatment. The main goal was to find the safest dose and understand side effects. Researchers also looked at…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
New drug combo may make bone marrow transplants safer for blood cancer patients
Disease control CompletedThis early-phase trial tested replacing the standard drug cyclophosphamide with bendamustine after a half-matched bone marrow transplant in 50 patients with various blood cancers. The goal was to see if this change could reduce side effects like graft-versus-host disease while st…
Phase 1 • Sponsor: University of Arizona • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC